May 2020: SanoStem is requesting Emergency Importation Approval from Indian Health Regulators for Stemedica’s Ischemic-Tolerant Allogeneic Mesenchymal Bone Marrow Stem Cells (itMSC or SanoMSC) to treat COVID-19 patients in India. SanoStem will provide 10 free treatments to COVID patients with serious Lung Damage and Acute Respiratory Distress Syndrome (ARDS).
May 2018: SanoStem has applied to CDSCO for approval of a Phase II/III clinical trial using itMSC for Type 2 Diabetes Mellitus (T2DM) in India. The principal investigators will be: Dr. Anil Bhansali, Professor Head of Department, PGIMER, Chandigarh and Dr. Sandeep Kumar Mathur, Professor Head of Department, S.M.S Medical College, Jaipur, Govt. of Rajasthan.
August 2014: SanoStem received approval from the Health Authority of Fiji to begin a clinical trial for ischemic stroke using both itNSC & itMSC.
2013-2020: Stemedica has FDA approval for 6 Phase I/IIa clinical trials in USA:
- Ischemic Stroke – Phase IIa completed and published.
- Congestive Heart Failure (CHF) Phase IIa completed & published.
- Acute Myocardial Infarction (AMI)
- Cutaneous PhotoAging
- Alzheimer’s Disease (AD)
- Traumatic Brain Injury (TBI